Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 29

1.

Metabolomic analysis of serum may refine 21-gene expression assay risk recurrence stratification.

McCartney A, Vignoli A, Tenori L, Fornier M, Rossi L, Risi E, Luchinat C, Biganzoli L, Di Leo A.

NPJ Breast Cancer. 2019 Aug 29;5:26. doi: 10.1038/s41523-019-0123-9. eCollection 2019.

2.

Mechanisms of Resistance to CDK4/6 Inhibitors: Potential Implications and Biomarkers for Clinical Practice.

McCartney A, Migliaccio I, Bonechi M, Biagioni C, Romagnoli D, De Luca F, Galardi F, Risi E, De Santo I, Benelli M, Malorni L, Di Leo A.

Front Oncol. 2019 Jul 23;9:666. doi: 10.3389/fonc.2019.00666. eCollection 2019. Review.

3.

Cyclin-Dependent Kinase 4/6 Inhibitors in Neoadjuvant Endocrine Therapy of Hormone Receptor-Positive Breast Cancer.

Rossi L, McCartney A, Risi E, De Santo I, Migliaccio I, Malorni L, Biganzoli L, Di Leo A.

Clin Breast Cancer. 2019 Jun 11. pii: S1526-8209(19)30307-6. doi: 10.1016/j.clbc.2019.05.019. [Epub ahead of print] Review.

PMID:
31358432
4.

Distinct HR expression patterns significantly affect the clinical behavior of metastatic HER2+ breast cancer and degree of benefit from novel anti-HER2 agents in the real world setting.

Pizzuti L, Krasniqi E, Barchiesi G, Della Giulia M, Izzo F, Sanguineti G, Marchetti P, Mazzotta M, Giusti R, Botticelli A, Gamucci T, Natoli C, Grassadonia A, Tinari N, Iezzi L, Tomao S, Tomao F, Tonini G, Santini D, Astone A, Michelotti A, De Angelis C, Mentuccia L, Vaccaro A, Magnolfi E, Gelibter A, Magri V, Cortesi E, D'Onofrio L, Cassano A, Rossi E, Cazzaniga M, Moscetti L, Omarini C, Piacentini F, Fabbri MA, Scinto AF, Corsi D, Carbognin L, Bria E, La Verde N, Samaritani R, Garufi C, Barni S, Mirabelli R, Sarmiento R, Veltri EM, D'Auria G, Paris I, Giotta F, Lorusso V, Cardillo F, Landucci E, Mauri M, Ficorella C, Roselli M, Adamo V, Ricciardi GRR, Russo A, Berardi R, Pistelli M, Fiorio E, Cannita K, Sini V, D'Ostilio N, Foglietta J, Greco F, Zamagni C, Garrone O, Di Cocco B, Baldini E, Livi L, Desideri I, Meattini I, Sarobba G, Del Medico P, De Tursi M, Generali D, De Maria R, Risi E, Ciliberto G, Sperduti I, Villa A, Barba M, Di Leo A, Vici P.

Int J Cancer. 2019 Jul 22. doi: 10.1002/ijc.32583. [Epub ahead of print]

PMID:
31330065
5.

Clinical outcomes after palbociclib with or without endocrine therapy in postmenopausal women with hormone receptor positive and HER2-negative metastatic breast cancer enrolled in the TREnd trial.

Rossi L, Biagioni C, McCartney A, Migliaccio I, Curigliano G, Sanna G, Moretti E, Minisini AM, Cinieri S, Tondini C, Arpino G, Bernardo A, Martignetti A, Risi E, Pestrin M, Boni L, Benelli M, Biganzoli L, Di Leo A, Malorni L.

Breast Cancer Res. 2019 May 29;21(1):71. doi: 10.1186/s13058-019-1149-5.

6.

The optimal duration of adjuvant endocrine therapy in early luminal breast cancer: A concise review.

Rossi L, McCartney A, De Santo I, Risi E, Moretti E, Malorni L, Biganzoli L, Di Leo A.

Cancer Treat Rev. 2019 Mar;74:29-34. doi: 10.1016/j.ctrv.2019.01.007. Epub 2019 Jan 25. Review.

PMID:
30708267
7.

Managing advanced HR-positive, HER2-negative breast cancer with CDK4/6 inhibitors in post-menopausal patients: is there a best sequence?

Rossi L, McCartney A, Risi E, Malorni L, Biganzoli L, Di Leo A.

Ther Adv Med Oncol. 2018 Dec 10;10:1758835918815591. doi: 10.1177/1758835918815591. eCollection 2018.

8.

Platinum-based Agent and Fluorouracil in Metastatic Breast Cancer: A Retrospective Monocentric Study with a Review of the Literature.

Rossi L, Biagioni C, McCartney A, Moretti E, Pestrin M, Sanna G, Risi E, Malorni L, DI Leo A, Biganzoli L.

Anticancer Res. 2018 Aug;38(8):4839-4845. doi: 10.21873/anticanres.12795.

PMID:
30061257
9.

The role of abemaciclib in treatment of advanced breast cancer.

McCartney A, Moretti E, Sanna G, Pestrin M, Risi E, Malorni L, Biganzoli L, Di Leo A.

Ther Adv Med Oncol. 2018 May 31;10:1758835918776925. doi: 10.1177/1758835918776925. eCollection 2018. Review.

10.

Palbociclib as single agent or in combination with the endocrine therapy received before disease progression for estrogen receptor-positive, HER2-negative metastatic breast cancer: TREnd trial.

Malorni L, Curigliano G, Minisini AM, Cinieri S, Tondini CA, D'Hollander K, Arpino G, Bernardo A, Martignetti A, Criscitiello C, Puglisi F, Pestrin M, Sanna G, Moretti E, Risi E, Biagioni C, McCartney A, Boni L, Buyse M, Migliaccio I, Biganzoli L, Di Leo A.

Ann Oncol. 2018 Aug 1;29(8):1748-1754. doi: 10.1093/annonc/mdy214.

11.

A gene expression signature of Retinoblastoma loss-of-function predicts resistance to neoadjuvant chemotherapy in ER-positive/HER2-positive breast cancer patients.

Risi E, Grilli A, Migliaccio I, Biagioni C, McCartney A, Guarducci C, Bonechi M, Benelli M, Vitale S, Biganzoli L, Bicciato S, Di Leo A, Malorni L.

Breast Cancer Res Treat. 2018 Jul;170(2):329-341. doi: 10.1007/s10549-018-4766-2. Epub 2018 Mar 22.

PMID:
29564743
12.

Mechanisms of Resistance to CDK4/6 Inhibitors in Breast Cancer and Potential Biomarkers of Response.

Guarducci C, Bonechi M, Boccalini G, Benelli M, Risi E, Di Leo A, Malorni L, Migliaccio I.

Breast Care (Basel). 2017 Oct;12(5):304-308. doi: 10.1159/000484167. Epub 2017 Oct 27. Review.

13.

Impact of body mass index on the clinical outcomes of patients with HER2-positive metastatic breast cancer.

Martel S, Poletto E, Ferreira AR, Lambertini M, Sottotetti F, Bertolini I, Montemurro F, Bernardo A, Risi E, Zanardi E, Ziliani S, Mura S, Dellepiane C, Del Mastro L, Minisini AM, Puglisi F.

Breast. 2018 Feb;37:142-147. doi: 10.1016/j.breast.2017.11.004. Epub 2017 Nov 21.

14.

Effects of deslorelin acetate on plasma testosterone concentrations in captive yellow-bellied sliders (Trachemys scripta sp.).

Potier R, Monge E, Loucachevsky T, Hermes R, Göritz F, Rochel D, Risi E.

Acta Vet Hung. 2017 Sep;65(3):440-445. doi: 10.1556/004.2017.041.

PMID:
28956487
15.

Patterns of Care and Clinical Outcomes of HER2-positive Metastatic Breast Cancer Patients With Newly Diagnosed Stage IV or Recurrent Disease Undergoing First-line Trastuzumab-based Therapy: A Multicenter Retrospective Cohort Study.

Lambertini M, Ferreira AR, Di Meglio A, Poggio F, Puglisi F, Sottotetti F, Montemurro F, Poletto E, Bernardo A, Risi E, Dellepiane C, Sini V, Minuti G, Grasso D, Fancelli S, Del Mastro L.

Clin Breast Cancer. 2017 Dec;17(8):601-610.e2. doi: 10.1016/j.clbc.2017.04.002. Epub 2017 Apr 11.

PMID:
28479052
16.

No pain, no gain… What we can learn from a trial reporting negative results.

Di Leo A, Risi E, Biganzoli L.

Ann Oncol. 2017 Apr 1;28(4):678-680. doi: 10.1093/annonc/mdx065. No abstract available.

PMID:
28327956
17.

Serum Metabolomic Profiles Identify ER-Positive Early Breast Cancer Patients at Increased Risk of Disease Recurrence in a Multicenter Population.

Hart CD, Vignoli A, Tenori L, Uy GL, Van To T, Adebamowo C, Hossain SM, Biganzoli L, Risi E, Love RR, Luchinat C, Di Leo A.

Clin Cancer Res. 2017 Mar 15;23(6):1422-1431. doi: 10.1158/1078-0432.CCR-16-1153. Epub 2017 Jan 12.

18.

Treatment of Metastatic Colorectal Cancer Patients ≥75 Years Old in Clinical Practice: A Multicenter Analysis.

Grande R, Natoli C, Ciancola F, Gemma D, Pellegrino A, Pavese I, Garufi C, Di Lauro L, Corsi D, Signorelli D, Sperduti I, Cortese G, Risi E, Morano F, Sergi D, Signorelli C, Ruggeri EM, Zampa G, Russano M, Gamucci T.

PLoS One. 2016 Jul 21;11(7):e0157751. doi: 10.1371/journal.pone.0157751. eCollection 2016.

19.

Using CTCs for pharmacogenomic analysis.

Hart CD, Galardi F, Pestrin M, De Luca F, Risi E, Di Leo A.

Pharmacol Res. 2016 Apr;106:92-100. doi: 10.1016/j.phrs.2016.02.019. Epub 2016 Feb 24. Review.

PMID:
26921662
20.

Patterns of Care and Clinical Outcomes of First-Line Trastuzumab-Based Therapy in HER2-Positive Metastatic Breast Cancer Patients Relapsing After (Neo)Adjuvant Trastuzumab: An Italian Multicenter Retrospective Cohort Study.

Lambertini M, Ferreira AR, Poggio F, Puglisi F, Bernardo A, Montemurro F, Poletto E, Pozzi E, Rossi V, Risi E, Lai A, Zanardi E, Sini V, Ziliani S, Minuti G, Mura S, Grasso D, Fontana A, Del Mastro L.

Oncologist. 2015 Aug;20(8):880-9. doi: 10.1634/theoncologist.2015-0020. Epub 2015 Jun 22.

21.

Standard of care and promising new agents for triple negative metastatic breast cancer.

Mancini P, Angeloni A, Risi E, Orsi E, Mezi S.

Cancers (Basel). 2014 Oct 24;6(4):2187-223. doi: 10.3390/cancers6042187. Review.

22.

Control of reproduction in ferrets, rabbits and rodents.

Risi E.

Reprod Domest Anim. 2014 Jun;49 Suppl 2:81-6. doi: 10.1111/rda.12300.

PMID:
24947865
23.

Clinical and pathological features of primary neuroectodermal tumor/Ewing sarcoma of the kidney.

Risi E, Iacovelli R, Altavilla A, Alesini D, Palazzo A, Mosillo C, Trenta P, Cortesi E.

Urology. 2013 Aug;82(2):382-6. doi: 10.1016/j.urology.2013.04.015. Epub 2013 Jun 22.

PMID:
23800653
24.

Multimodality treatment of gynecomastia in patients receiving antiandrogen therapy for prostate cancer in the era of abiraterone acetate and new antiandrogen molecules.

Alesini D, Iacovelli R, Palazzo A, Altavilla A, Risi E, Urbano F, Manai C, Passaro A, Magri V, Cortesi E.

Oncology. 2013;84(2):92-9. doi: 10.1159/000343821. Epub 2012 Nov 2. Review.

PMID:
23128186
25.

Medical strategies for treatment of castration resistant prostate cancer (CRPC) docetaxel resistant.

Altavilla A, Iacovelli R, Procopio G, Alesini D, Risi E, Campennì GM, Palazzo A, Cortesi E.

Cancer Biol Ther. 2012 Sep;13(11):1001-8. doi: 10.4161/cbt.21188. Epub 2012 Jul 24. Review.

26.

Antibody response to vaccines for rhinotracheitis, caliciviral disease, panleukopenia, feline leukemia, and rabies in tigers (Panthera tigris) and lions (Panthera leo).

Risi E, Agoulon A, Allaire F, Le Dréan-Quénec'hdu S, Martin V, Mahl P.

J Zoo Wildl Med. 2012 Jun;43(2):248-55.

PMID:
22779227
27.

Genital and inguinal cutaneous toxicity in male and female patients treated with sunitinib.

Iacovelli R, Mancini ML, Risi E, Palazzo A, Cortesi E.

Int J Dermatol. 2012 Feb;51(2):221-2. doi: 10.1111/j.1365-4632.2011.05057.x.

PMID:
22250635
28.

High-grade mucoepidermoid carcinoma of the mandibular salivary gland in a lion (Panthera leo).

Dorso L, Risi E, Triau S, Labrut S, Nguyen F, Guigand L, Wyers M, Abadie J.

Vet Pathol. 2008 Jan;45(1):104-8. doi: 10.1354/vp.45-1-104.

PMID:
18192586
29.

[Treatment of breast injuries in marine ducks hospitalized at a wildlife shelter].

Risi E, Ferlaux C, Sauteur N, Le Dréan-Quénec'hdu S.

Can Vet J. 2001 Sep;42(9):708-13. French.

Supplemental Content

Support Center